Nventa Biopharmaceuticals Corporation to Present at Upcoming Investor Conferences

Published: Sep 03, 2008

SAN DIEGO, Sept. 3 /PRNewswire-FirstCall/ -- Nventa Biopharmaceuticals Corporation today announced that the company will present corporate updates at a number of upcoming industry and financial conferences. Nventa's presentations will focus on HspE7, the company's lead product candidate for the treatment of human papillomavirus (HPV)-related diseases, as well as the company's proprietary Toll-like Receptor 3 (TLR3) agonist vaccine adjuvant program and additional corporate developments.

Upcoming conferences at which the company will present include:

-- The Wall Street Analyst Forum, on September 10, 2008, at 10:30 a.m. (ET) at The University Club, 1 West 54th Street (corner of 54th Street & 5th Avenue) in New York City. A live webcast will be available on the company's website at http://www.nventacorp.com and archived for 60 days.

-- Sachs Associates' 8th Annual Biotech in Europe Investor Forum, on September 23, 2008, at 12:25 pm (CET) in Zurich, Switzerland.

-- TSX and the Equicom Group "On the Radar" on September 25, 2008, at 12:00 p.m. (ET) at Canoe Restaurant, 54th Floor, TD Tower, 66 Wellington Street West, Toronto, Canada. An audio webcast will be archived on the company's website at http://www.nventacorp.com following the presentation and remain available for 60 days.

About Nventa Biopharmaceuticals Corporation:

Nventa is developing innovative therapeutics incorporating its proprietary CoVal(TM) fusions for the treatment of viral infections and cancers, with a focus on diseases caused by the human papillomavirus (HPV); and a Toll-like Receptor 3 (TLR3) agonist for use as a vaccine adjuvant and as an immunotherapeutic for viral infections and cancer. The company is publicly traded on the Toronto Stock Exchange under the symbol "NVN". For more information about Nventa Biopharmaceuticals Corporation, please visit the company's website located at http://www.nventacorp.com.

CONTACT: Donna Slade, Director, Investor Relations of Nventa
Biopharmaceuticals Corporation, +1-858-202-4945, dslade@nventacorp.com; or
media, Tim Brons of Vida Communication, +1-415-675-7402,
tbrons@vidacommunication.com; or Michael Moore of The Equicom Group,
+1-416-815-0700, ext. 241, mmoore@equicomgroup.com, both for Nventa
Biopharmaceuticals Corporation

Web site: http://www.nventacorp.com/

Back to news